menu
    • menu
    [{"orgOrder":0,"company":"Edding Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Edding Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Edding Pharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Edding Pharm \/ Not Applicable"},{"orgOrder":0,"company":"Edding Pharm","sponsor":"Amarin","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Edding Pharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Edding Pharm \/ Edding","highestDevelopmentStatusID":"12","companyTruncated":"Edding Pharm \/ Edding"},{"orgOrder":0,"company":"Edding Pharm","sponsor":"Amarin","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Edding Pharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Edding Pharm \/ Edding Pharm","highestDevelopmentStatusID":"12","companyTruncated":"Edding Pharm \/ Edding Pharm"},{"orgOrder":0,"company":"Edding Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Edding Pharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Edding Pharm \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Edding Pharm \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Edding Pharm

    Menu

    Edding Pharm

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Edding Pharm

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Edding Pharm

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amarin Partner EddingPharm Gets Approval for VASCEPA® in China for CVRR

                            Details : Vascepa (icosapent ethyl) is an ethyl ester of eicosapentaenoic acid (EPA) which is indicated to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina.

                            Brand Name : Vascepa

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 08, 2024

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Edding Pharm

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Edding Pharm

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Recipient : Amarin

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa (Icosapent Ethyl) in Mainland China

                            Details : VASCEPA®/VAZKEPA® (icosapent ethyl) Capsules first prescription treatment approved by the FDA comprised solely of the active ingredient, icosapent ethyl, a unique form of eicosapentaenoic acid for the treatment of adult patients with severe Hypertrigly...

                            Brand Name : Vascepa

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 01, 2023

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Recipient : Amarin

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Edding Pharm

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Edding Pharm

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Recipient : Amarin

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amarin Provides Update on Vascepa® (Icosapent Ethyl) Regulatory Review Processes in Mainland China and Hong K...

                            Details : Edding is seeking labeling based on the entirety of clinical data available for VASCEPA, including the previously announced successful results of the Phase 3 study conducted by Edding as well as studies conducted by Amarin.

                            Brand Name : Vascepa

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 09, 2021

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Recipient : Amarin

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Edding Pharm

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Edding Pharm

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amarin Shares Topline Data from Partner’s Pivotal Phase 3 Study of VASCEPA® (Icosapent Ethyl) in Mainland C...

                            Details : The study, investigating VASCEPA for patients with very high triglycerides, met its primary efficacy endpoint and showed safety profile similar to placebo. The findings are being prepared to support Edding’s dossier for seeking regulatory approval of V...

                            Brand Name : Vascepa

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 19, 2020

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth